ISCT Conference

Following Diamyd Medical’s negative results from the March 27 interim analysis of its DIAGNODE-3 study, the Board of Directors has implemented governance changes to strengthen oversight and strategic direction.

Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).

Elicera Therapeutics has resolved to carry out a rights issue of shares of approximately SEK 72.8 million with preferential rights for the company’s existing shareholders.

The purpose of the Karolinska Institutet Centre for AI Innovation is to serve as a support centre and skills hub.

CEPI and the Recipharm company Analysis Zero have announced a new seed collaboration to advance the use of Nuclear Magnetic Resonance (NMR) as a real-time Process Analytical Technology (PAT) for RNA vaccine manufacturing.

The company has appointed Margarida Duarte as General Manager, Europe and Emerging Markets, as the company continues to scale its commercialization presence.

The company has announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma (GBM) and other high-grade gliomas.